Sandoz Launches Generic Gefitinib for Locally Advanced or Metastatic Non-Small Cell Lung Cancer in 13 European Countries

 Sandoz Launches Generic Gefitinib for Locally Advanced or Metastatic Non-Small Cell Lung Cancer in 13 European Countries

Sandoz Launches Generic Gefitinib for Locally Advanced or Metastatic Non-Small Cell Lung Cancer in 13 European Countries

Shots:

  • The launch of generic oncology therapy Gefitinib will follow the loss of market exclusivity of the reference product with the already expired patent protection
  • The Gefitinib is listed in national essential medicines for cancer, indicated to treat LA or m-NSCLC with activating mutations of EGFR-TK and will be available in 13 EU countries with its expected availability in other countries
  • Gefitinib (qd) is a non-CT therapy, recommended by ESMO as 1L therapy for EGFR-activating mutation metastatic NSCLC and has received European regulatory approval for the generic molecule in July’18

Click here to read full press release/ article | Ref: Novartis | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post